Author results

4MOD
  • Download 4mod
  • View 4mod
Molmil generated image of 4mod
STRUCTURE OF THE MERS-COV FUSION CORE
Descriptor:HR1 of S protein, LINKER, HR2 of S protein
Authors:Gao, J., Lu, G., Qi, J., Li, Y., Wu, Y., Deng, Y., Geng, H., Xiao, H., Tan, W., Yan, J., Gao, G.F.
Deposit date:2013-09-12
Release date:2013-10-09
Last modified:2017-06-28
Method:X-RAY DIFFRACTION (1.901 Å)
Cite:Structure of the fusion core and inhibition of fusion by a heptad-repeat peptide derived from the S protein of MERS-CoV
J.Virol., 2013
6DE7
  • Download 6de7
  • View 6de7
Molmil generated image of 6de7
CRYSTAL STRUCTURE AT 4.3 A RESOLUTION OF GLYCOSYLATED HIV-1 CLADE A BG505 SOSIP.664 PREFUSION ENV TRIMER WITH INTERDOMAIN STABILIZATION 113C-429GCG IN COMPLEX WITH BROADLY NEUTRALIZING ANTIBODIES PGT122 AND 35O22
Descriptor:Envelope glycoprotein gp160, 35O22 heavy chain, 35O22 light chain, ...
Authors:Gorman, J., Kwong, P.D.
Deposit date:2018-05-11
Release date:2018-06-06
Last modified:2018-06-27
Method:X-RAY DIFFRACTION (4.123 Å)
Cite:Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer.
Cell Host Microbe, 23, 2018
5TKJ
  • Download 5tkj
  • View 5tkj
Molmil generated image of 5tkj
STRUCTURE OF VACCINE-ELICITED DIVERSE HIV-1 NEUTRALIZING ANTIBODY VFP1.01 IN COMPLEX WITH HIV-1 FUSION PEPTIDE RESIDUE 512-519
Descriptor:vFP1.01 chimeric mouse antibody heavy chain, vFP1.01 chimeric mouse antibody light chain, HIV-1 fusion peptide residue 512-519, ...
Authors:Xu, K., Liu, K., Kwong, P.D.
Deposit date:2016-10-06
Release date:2018-04-04
Last modified:2018-06-27
Method:X-RAY DIFFRACTION (2.118 Å)
Cite:Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
5TKK
  • Download 5tkk
  • View 5tkk
Molmil generated image of 5tkk
STRUCTURE OF MOUSE VACCINATION-ELICITED HIV NEUTRALIZING ANTIBODY VFP5.01 IN COMPLEX WITH HIV-1 FUSION PEPTIDE RESIDUE 512-519
Descriptor:HIV-1 fusion peptide residue 512-519, mouse antibody vFP5.01 heavy chain, mouse antibody vFP5.01 light chain
Authors:Xu, K., Liu, K., Kwong, P.D.
Deposit date:2016-10-06
Release date:2018-04-04
Last modified:2018-06-27
Method:X-RAY DIFFRACTION (1.55 Å)
Cite:Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
6CDE
  • Download 6cde
  • View 6cde
Molmil generated image of 6cde
CRYO-EM STRUCTURE AT 3.8 A RESOLUTION OF VACCINE-ELICITED ANTIBODY VFP20.01 IN COMPLEX WITH HIV-1 ENV BG505 DS-SOSIP, AND ANTIBODIES VRC03 AND PGT122
Descriptor:vFP20.01 Heavy Chain, vFP20.01 Light chain, PGT122 Heavy chain, ...
Authors:Acharya, P., Xu, K., Liu, K., Carragher, B., Potter, C.S., Kwong, P.D.
Deposit date:2018-02-08
Release date:2018-05-16
Last modified:2018-06-20
Method:ELECTRON MICROSCOPY (3.8 Å)
Cite:Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
6CDI
  • Download 6cdi
  • View 6cdi
Molmil generated image of 6cdi
CRYO-EM STRUCTURE AT 3.6 A RESOLUTION OF VACCINE-ELICITED ANTIBODY VFP16.02 IN COMPLEX WITH HIV-1 ENV BG505 DS-SOSIP, AND ANTIBODIES VRC03 AND PGT122
Descriptor:Glycoprotein gp41, Glycoprotein 120, PGT122 Light Chain, ...
Authors:Acharya, P., Xu, K., Liu, K., Carragher, B., Potter, C.S., Kwong, P.D.
Deposit date:2018-02-08
Release date:2018-05-16
Last modified:2019-02-20
Method:ELECTRON MICROSCOPY (3.6 Å)
Cite:Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
6CDM
  • Download 6cdm
  • View 6cdm
Molmil generated image of 6cdm
STRUCTURE OF VACCINE-ELICITED HIV-1 NEUTRALIZING ANTIBODY VFP7.04 IN COMPLEX WITH HIV-1 FUSION PEPTIDE RESIDUE 512-519
Descriptor:vFP7.04 heavy chain, vFP7.04 light chain, HIV fusion peptide (512-519)
Authors:Xu, K., Liu, K., Kwong, P.D.
Deposit date:2018-02-08
Release date:2018-05-16
Last modified:2018-06-20
Method:X-RAY DIFFRACTION (2.408 Å)
Cite:Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
6CDO
  • Download 6cdo
  • View 6cdo
Molmil generated image of 6cdo
STRUCTURE OF VACCINE-ELICITED HIV-1 NEUTRALIZING ANTIBODY VFP16.02 IN COMPLEX WITH HIV-1 FUSION PEPTIDE RESIDUE 512-519
Descriptor:vFP16.02 Fab heavy chain, vFP16.02 Fab light chain, HIV-1 fusion peptide 512-519, ...
Authors:Xu, K., Liu, K., Kwong, P.D.
Deposit date:2018-02-08
Release date:2018-05-16
Last modified:2018-06-20
Method:X-RAY DIFFRACTION (2.099 Å)
Cite:Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
6CDP
  • Download 6cdp
  • View 6cdp
Molmil generated image of 6cdp
VACCINE-ELICITED HIV-1 NEUTRALIZING ANTIBODY VFP20.01 IN COMPLEX WITH HIV-1 FUSION PEPTIDE RESIDUE 512-519
Descriptor:vFP20.01 Fab heavy chain, vFP20.01 Fab light chain, HIV-1 fusion peptide 512-519, ...
Authors:Xu, K., Liu, K., Kwong, P.D.
Deposit date:2018-02-08
Release date:2018-05-16
Last modified:2018-06-20
Method:X-RAY DIFFRACTION (2.456 Å)
Cite:Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat. Med., 24, 2018
5U7M
  • Download 5u7m
  • View 5u7m
Molmil generated image of 5u7m
CRYSTAL STRUCTURE OF HIV-1 BG505 SOSIP.664 PREFUSION ENV TRIMER BOUND TO SMALL MOLECULE HIV-1 ENTRY INHIBITOR BMS-378806 IN COMPLEX WITH HUMAN ANTIBODIES PGT122 AND 35O22 AT 3.8 ANGSTROM
Descriptor:Envelope glycoprotein gp160, 35O22 FAB HEAVY CHAIN, 35O22 FAB LIGHT CHAIN, ...
Authors:Pancera, M., Lai, Y.-T., Kwong, P.D.
Deposit date:2016-12-12
Release date:2017-08-30
Last modified:2017-09-27
Method:X-RAY DIFFRACTION (3.025 Å)
Cite:Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.
Nat. Chem. Biol., 13, 2017
5U7O
  • Download 5u7o
  • View 5u7o
Molmil generated image of 5u7o
CRYSTAL STRUCTURE OF HIV-1 BG505 SOSIP.664 PREFUSION ENV TRIMER BOUND TO SMALL MOLECULE HIV-1 ENTRY INHIBITOR BMS-626529 IN COMPLEX WITH HUMAN ANTIBODIES PGT122 AND 35O22 AT 3.8 ANGSTROM
Descriptor:Envelope glycoprotein gp160, 35O22 FAB HEAVY CHAIN, 35O22 FAB LIGHT CHAIN, ...
Authors:Pancera, M., Lai, Y.-T., Kwong, P.D.
Deposit date:2016-12-12
Release date:2017-08-30
Last modified:2017-10-18
Method:X-RAY DIFFRACTION (3.031 Å)
Cite:Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529.
Nat. Chem. Biol., 13, 2017
5UTF
  • Download 5utf
  • View 5utf
Molmil generated image of 5utf
CRYSTAL STRUCTURE OF A STABILIZED DS-SOSIP.6MUT BG505 GP140 HIV-1 ENV TRIMER, CONTAINING MUTATIONS I201C-P433C (DS), L154M, Y177W, N300M, N302M, T320L, I420M IN COMPLEX WITH HUMAN ANTIBODIES PGT122 AND 35O22 AT 4.3 A
Descriptor:Envelope glycoprotein gp120, Envelope glycoprotein gp41, PGT122 Light chain, ...
Authors:Pancera, M., Chuang, G.-Y., Xu, K., Kwong, P.D.
Deposit date:2017-02-14
Release date:2017-03-29
Last modified:2017-05-10
Method:X-RAY DIFFRACTION (3.503 Å)
Cite:Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.
J. Virol., 91, 2017
5UTY
  • Download 5uty
  • View 5uty
Molmil generated image of 5uty
CRYSTAL STRUCTURE OF A STABILIZED DS-SOSIP.MUT4 BG505 GP140 HIV-1 ENV TRIMER, CONTAINING MUTATIONS I201C-P433C (DS), L154M, N300M, N302M, T320L IN COMPLEX WITH HUMAN ANTIBODIES PGT122 AND 35O22 AT 4.1 ANGSTROM
Descriptor:HIV-1 BG505 strain Env gp41, 35O22 Fab heavy chain, 35O22 Fab light chain, ...
Authors:Xu, K., Chuang, G.-Y., Pancera, M., Kwong, P.D.
Deposit date:2017-02-15
Release date:2017-03-29
Last modified:2017-11-22
Method:X-RAY DIFFRACTION (3.412 Å)
Cite:Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.
J. Virol., 91, 2017
5V7J
  • Download 5v7j
  • View 5v7j
Molmil generated image of 5v7j
CRYSTAL STRUCTURE AT 3.7 A RESOLUTION OF GLYCOSYLATED HIV-1 CLADE A BG505 SOSIP.664 PREFUSION ENV TRIMER WITH FOUR GLYCANS (N197, N276, N362, AND N462) REMOVED IN COMPLEX WITH NEUTRALIZING ANTIBODIES 3H+109L AND 35O22.
Descriptor:Envelope glycoprotein gp160, Antibody 3H+109L Fab light chain, Antibody 3H+109L Fab heavy chain, ...
Authors:Stewart-Jones, G.B.E., Zhou, T., Kwong, P.D.
Deposit date:2017-03-20
Release date:2017-06-21
Last modified:2017-09-13
Method:X-RAY DIFFRACTION (2.907 Å)
Cite:Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.
Cell Rep, 19, 2017
5ZZ2
  • Download 5zz2
  • View 5zz2
Molmil generated image of 5zz2
CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH INHIBITOR LW1634
Descriptor:cGMP-specific 3',5'-cyclic phosphodiesterase, ZINC ION, MAGNESIUM ION, ...
Authors:Wu, D., Huang, Y.D., Huang, Y.Y., Luo, H.B.
Deposit date:2018-05-29
Release date:2018-09-19
Last modified:2018-10-10
Method:X-RAY DIFFRACTION (2.6 Å)
Cite:Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.
J. Med. Chem., 61, 2018
6A3N
  • Download 6a3n
  • View 6a3n
Molmil generated image of 6a3n
CRYSTAL STRUCTURE OF THE PDE9 CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR 2
Descriptor:High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, ZINC ION, MAGNESIUM ION, ...
Authors:Wu, Y.N., Zhou, Q., Chen, Y.P., Luo, H.B.
Deposit date:2018-06-15
Release date:2019-04-10
Last modified:2019-05-08
Method:X-RAY DIFFRACTION (2.6 Å)
Cite:Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
J. Med. Chem., 62, 2019
6ACB
  • Download 6acb
  • View 6acb
Molmil generated image of 6acb
CRYSTAL STRUCTURE OF PDE5 IN COMPLEX WITH INHIBITOR LW1805
Descriptor:cGMP-specific 3',5'-cyclic phosphodiesterase, SULFATE ION, ZINC ION, ...
Authors:Wu, D., Huang, Y.D., Huang, Y.Y., Luo, H.B.
Deposit date:2018-07-26
Release date:2018-09-19
Last modified:2018-10-10
Method:X-RAY DIFFRACTION (2.8 Å)
Cite:Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.
J. Med. Chem., 61, 2018